Surgery and standard intravenous CHEMOTHERAPY with a platinum-taxane combination induce complete remission in most patients with newly DIAGNOSED ovarian cancer. However, most patients eventually relapse and die from their disease. Interest is growing in the intraperitoneal delivery of chemotherapy to patients with ovarian cancer who have minimal residual disease following INITIAL cytoreductive surgery. THREE randomized trials demonstrated an IMPROVEMENT in overall survival with intraperitoneal cisplatin compared with intravenous chemotherapy alone.

Surgery and standard intravenous chemotherapy with a platinum-taxane combination induce complete remission in most patients with newly diagnosed ovarian cancer. However, most patients eventually relapse and die from their disease. Interest is growing in the intraperitoneal delivery of chemotherapy to patients with ovarian cancer who have minimal residual disease following initial cytoreductive surgery. Three randomized trials demonstrated an improvement in overall survival with intraperitoneal cisplatin compared with intravenous chemotherapy alone.